Press releases
- LivaNova to Announce First-Quarter 2024 Results
- LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
- LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
- LivaNova to Present at the Barclays Global Healthcare Conference
- LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
- LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 35.93 |
Offer | 36.10 |
Previous close | 41.65 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 24 2024 20:49 BST.
More ▼